中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 12
Dec.  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(12): 2513-2517

Mechanism of action of disulfidptosis in nonalcoholic fatty liver disease

DOI: 10.12449/JCH241223
  • a.

    College of Clinical Medical Sciences, Jilin Medical University，Jilin，Jilin 132013，China

  • b.

    College of Basic Medical Sciences，Jilin Medical University，Jilin，Jilin 132013，China

Research funding:

Jilin Natural Science Foundation Project (YDZJ202201ZYTS145);

Jilin Provincial Education Department Project (JJKH20210488KJ);

Program for College Students’ Innovation and Entrepreneurship Training of Jilin Medical University (202313706002)

More Information
  • Corresponding author: FENG Xianmin， fengxianmin28 @163.com （ORCID： 0000-0002-5079-350X）; SUN Jie， sunjie1014@163.com （ORCID： 0009-0008-5226-9366）
  • Received Date: 2024-08-21
  • Accepted Date: 2024-09-10
  • Published Date: 2024-12-25
    Abstract
  • Disulfidptosis is a novel pattern of cell death caused by disulfide stress and inadequate NADPH. Nonalcoholic fatty liver disease （NAFLD） is a group of metabolic diseases with the main pathological feature of fatty infiltration， and it is closely associated with insulin resistance and genetic susceptibility. Currently， the latest studies have shown that disulfide stress caused by disulfidptosis can result in hepatocyte death， thereby accelerating the progression of NAFLD. This article summarizes and analyzes the latest studies on disulfidptosis in NAFLD， in order to explore the application of disulfidptosis in NAFLD and provide new ideas for the prevention and treatment of NAFLD.

     

    • FullText(HTML)
    • References(50)
  • [1]
    AMORIM R, SOARES P, CHAVARRIA D, et al. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities[J]. Eur J Med Chem, 2024, 277: 116723. DOI: 10.1016/j.ejmech.2024.116723.
    [2]
    YANG BM, TANG GM, WANG MT, et al. Trimethylamine N-oxide induces non-alcoholic fatty liver disease by activating the PERK[J]. Toxicol Lett, 2024, 400: 93- 103. DOI: 10.1016/j.toxlet.2024.08.009.
    [3]
    YOUNOSSI ZM, GOLABI P, PAIK JM, et al. The global epidemiology of nonalcoholic fatty liver disease(NAFLD) and nonalcoholic steatohepatitis(NASH): A systematic review[J]. Hepatology, 2023, 77( 4): 1335- 1347. DOI: 10.1097/HEP.0000000000000004.
    [4]
    LUO XH, GUO JJ, DENG HB, et al. Unveiling the role of disulfidptosis-related genes in the pathogenesis of non-alcoholic fatty liver disease[J]. Front Immunol, 2024, 15: 1386905. DOI: 10.3389/fimmu.2024.1386905.
    [5]
    LIU XG, NIE LT, ZHANG YL, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis[J]. Nat Cell Biol, 2023, 25( 3): 404- 414. DOI: 10.1038/s41556-023-01091-2.
    [6]
    ZHENG TJ, LIU QB, XING FY, et al. Disulfidptosis: A new form of programmed cell death[J]. J Exp Clin Cancer Res, 2023, 42( 1): 137. DOI: 10.1186/s13046-023-02712-2.
    [7]
    SARMIENTO-SALINAS FL, PEREZ-GONZALEZ A, ACOSTA-CASIQUE A, et al. Reactive oxygen species: Role in carcinogenesis, cancer cell signaling and tumor progression[J]. Life Sci, 2021, 284: 119942. DOI: 10.1016/j.lfs.2021.119942.
    [8]
    NJEIM R, ALKHANSA S, FORNONI A. Unraveling the crosstalk between lipids and NADPH oxidases in diabetic kidney disease[J]. Pharmaceutics, 2023, 15( 5): 1360. DOI: 10.3390/pharmaceutics15051360.
    [9]
    MUSAOGULLARI A, CHAI YC. Redox regulation by protein S-glutathionylation: From molecular mechanisms to implications in health and disease[J]. Int J Mol Sci, 2020, 21( 21): 8113. DOI: 10.3390/ijms21218113.
    [10]
    SHUAI Y, MA ZH, YUAN P. Disulfidptosis: Disulfide stress-induced novel cell death pathway[J]. MedComm(2020), 2024, 5( 7): e579. DOI: 10.1002/mco2.579.
    [11]
    YUE JD, YIN YK, FENG XJ, et al. Discovery of the inhibitor targeting the SLC7A11/xCT axis through in silico and in vitro experiments[J]. Int J Mol Sci, 2024, 25( 15): 8284. DOI: 10.3390/ijms25158284.
    [12]
    MACHESKY LM. Deadly actin collapse by disulfidptosis[J]. Nat Cell Biol, 2023, 25( 3): 375- 376. DOI: 10.1038/s41556-023-01100-4.
    [13]
    SHUBHRASMITA SAHU S, SARKAR P, CHATTOPADHYAY A. Quantitation of F-actin in cytoskeletal reorganization: Context, methodology and implications[J]. Methods, 2024, 230: 44- 58. DOI: 10.1016/j.ymeth.2024.07.009.
    [14]
    YANG GN, KOPECKI Z, COWIN AJ. Role of actin cytoskeleton in the regulation of epithelial cutaneous stem cells[J]. Stem Cells Dev, 2016, 25( 10): 749- 759. DOI: 10.1089/scd.2016.0051.
    [15]
    DEWANE G, SALVI AM, DEMALI KA. Fueling the cytoskeleton-links between cell metabolism and actin remodeling[J]. J Cell Sci, 2021, 134( 3): jcs248385. DOI: 10.1242/jcs.248385.
    [16]
    JYOTSANA N, TA KT, DELGIORNO KE. The role of cystine/glutamate antiporter SLC7A11/xCT in the pathophysiology of cancer[J]. Front Oncol, 2022, 12: 858462. DOI: 10.3389/fonc.2022.858462.
    [17]
    XU ZC, WANG YP, YANG WL, et al. Total extracts from Abelmoschus manihot(L.) alleviate radiation-induced cardiomyocyte ferroptosis via regulating redox imbalances mediated by the NOX4/xCT/GPX4 axis[J]. J Ethnopharmacol, 2024, 334: 118582. DOI: 10.1016/j.jep.2024.118582.
    [18]
    COSTA I, BARBOSA DJ, BENFEITO S, et al. Molecular mechanisms of ferroptosis and their involvement in brain diseases[J]. Pharmacol Ther, 2023, 244: 108373. DOI: 10.1016/j.pharmthera.2023.108373.
    [19]
    KOPPULA P, ZHUANG L, GAN BY. Cystine transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient dependency, and cancer therapy[J]. Protein Cell, 2021, 12( 8): 599- 620. DOI: 10.1007/s13238-020-00789-5.
    [20]
    MURRAY TV, DONG X, SAWYER GJ, et al. NADPH oxidase 4 regulates homocysteine metabolism and protects against acetaminophen-induced liver damage in mice[J]. Free Radic Biol Med, 2015, 89: 918- 930. DOI: 10.1016/j.freeradbiomed.2015.09.015.
    [21]
    COLLET JF, CHO SH, IORGA BI, et al. How the assembly and protection of the bacterial cell envelope depend on cysteine residues[J]. J Biol Chem, 2020, 295( 34): 11984- 11994. DOI: 10.1074/jbc.REV120.011201.
    [22]
    ADEVA-ANDANY MM, PÉREZ-FELPETE N, FERNÁNDEZ-FERNÁNDEZ C, et al. Liver glucose metabolism in humans[J]. Biosci Rep, 2016, 36( 6): e00416. DOI: 10.1042/BSR20160385.
    [23]
    GARCÍA-DOMÍNGUEZ E, CARRETERO A, VIÑA-ALMUNIA A, et al. Glucose 6-P dehydrogenase-an antioxidant enzyme with regulatory functions in skeletal muscle during exercise[J]. Cells, 2022, 11( 19): 3041. DOI: 10.3390/cells11193041.
    [24]
    SONG WX, LI DY, TAO L, et al. Solute carrier transporters: The metabolic gatekeepers of immune cells[J]. Acta Pharm Sin B, 2020, 10( 1): 61- 78. DOI: 10.1016/j.apsb.2019.12.006.
    [25]
    YU XX, GUO ZH, FANG ZH, et al. Identification and validation of disulfidptosis-associated molecular clusters in non-alcoholic fatty liver disease[J]. Front Genet, 2023, 14: 1251999. DOI: 10.3389/fgene.2023.1251999.
    [26]
    AHMED B, SULTANA R, GREENE MW. Adipose tissue and insulin resistance in obese[J]. Biomed Pharmacother, 2021, 137: 111315. DOI: 10.1016/j.biopha.2021.111315.
    [27]
    AMINI-SALEHI E, LETAFATKAR N, NOROUZI N, et al. Global prevalence of nonalcoholic fatty liver disease: An updated review meta-analysis comprising a population of 78 million from 38 countries[J]. Arch Med Res, 2024, 55( 6): 103043. DOI: 10.1016/j.arcmed.2024.103043.
    [28]
    OH AR, JEONG Y, YU JJ, et al. Hepatocyte Kctd17 inhibition ameliorates glucose intolerance and hepatic steatosis caused by obesity-induced chrebp stabilization[J]. Gastroenterology, 2023, 164( 3): 439- 453. DOI: 10.1053/j.gastro.2022.11.019.
    [29]
    ATORRASAGASTI C, ONORATO AM, MAZZOLINI G. The role of SPARC(secreted protein acidic and rich in cysteine) in the pathogenesis of obesity, type 2 diabetes, and non-alcoholic fatty liver disease[J]. J Physiol Biochem, 2023, 79( 4): 815- 831. DOI: 10.1007/s13105-022-00913-5.
    [30]
    AJOOLABADY A, KAPLOWITZ N, LEBEAUPIN C, et al. Endoplasmic reticulum stress in liver diseases[J]. Hepatology, 2023, 77( 2): 619- 639. DOI: 10.1002/hep.32562.
    [31]
    CELIK C, LEE SYT, YAP WS, et al. Endoplasmic reticulum stress and lipids in health and diseases[J]. Prog Lipid Res, 2023, 89: 101198. DOI: 10.1016/j.plipres.2022.101198.
    [32]
    LIANG YC, KAUSHAL D, WILSON RB. Cellular senescence and extracellular vesicles in the pathogenesis and treatment of obesity-A narrative review[J]. Int J Mol Sci, 2024, 25( 14): 7943. DOI: 10.3390/ijms25147943.
    [33]
    de ALMEIDA CHUFFA LG, SEIVA FRF, SILVEIRA HS, et al. Melatonin regulates endoplasmic reticulum stress in diverse pathophysiological contexts: A comprehensive mechanistic review[J]. J Cell Physiol, 2024: e31383. DOI: 10.1002/jcp.31383.
    [34]
    ZHANG J, GUO JF, YANG NN, et al. Endoplasmic reticulum stress-mediated cell death in liver injury[J]. Cell Death Dis, 2022, 13( 12): 1051. DOI: 10.1038/s41419-022-05444-x.
    [35]
    SIMÕES ICM, AMORIM R, TEIXEIRA J, et al. The alterations of mitochondrial function during NAFLD progression-an independent effect of mitochondrial ROS production[J]. Int J Mol Sci, 2021, 22( 13): 6848. DOI: 10.3390/ijms22136848.
    [36]
    KARKUCINSKA-WIECKOWSKA A, SIMOES ICM, KALINOWSKI P, et al. Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship[J]. Eur J Clin Invest, 2022, 52( 3): e13622. DOI: 10.1111/eci.13622.
    [37]
    LIU XG, ZHUANG L, GAN BY. Disulfidptosis: Disulfide stress-induced cell death[J]. Trends Cell Biol, 2024, 34( 4): 327- 337. DOI: 10.1016/j.tcb.2023.07.009.
    [38]
    JOLY JH, DELFARAH A, PHUNG PS, et al. A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose[J]. J Biol Chem, 2020, 295( 5): 1350- 1365. DOI: 10.1074/jbc.RA119.011471.
    [39]
    HORNA-TERRÓN E, PRADILLA-DIESTE A, SÁNCHEZ-DE-DIEGO C, et al. TXNDC5, a newly discovered disulfide isomerase with a key role in cell physiology and pathology[J]. Int J Mol Sci, 2014, 15( 12): 23501- 23518. DOI: 10.3390/ijms151223501.
    [40]
    NATH B, SZABO G. Hypoxia and hypoxia inducible factors: Diverse roles in liver diseases[J]. Hepatology, 2012, 55( 2): 622- 633. DOI: 10.1002/hep.25497.
    [41]
    GONG H, HE QD, ZHU LL, et al. Associations between systemic inflammation indicators and nonalcoholic fatty liver disease: Evidence from a prospective study[J]. Front Immunol, 2024, 15: 1389967. DOI: 10.3389/fimmu.2024.1389967.
    [42]
    LIU Q, BENGMARK S, QU S. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J]. Lipids Health Dis, 2010, 9: 42. DOI: 10.1186/1476-511X-9-42.
    [43]
    BURGER D, FICKENTSCHER C, de MOERLOOSE P, et al. F-actin dampens NLRP3 inflammasome activity via Flightless-I and LRRFIP2[J]. Sci Rep, 2016, 6: 29834. DOI: 10.1038/srep29834.
    [44]
    de CARVALHO RIBEIRO M, SZABO G. Role of the inflammasome in liver disease[J]. Annu Rev Pathol, 2022, 17: 345- 365. DOI: 10.1146/annurev-pathmechdis-032521-102529.
    [45]
    YU LL, HONG W, LU S, et al. The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: Therapeutic targets and treatment[J]. Front Pharmacol, 2022, 13: 780496. DOI: 10.3389/fphar.2022.780496.
    [46]
    LEE PP, LOBATO-MÁRQUEZ D, PRAMANIK N, et al. Wiskott-Aldrich syndrome protein regulates autophagy and inflammasome activity in innate immune cells[J]. Nat Commun, 2017, 8( 1): 1576. DOI: 10.1038/s41467-017-01676-0.
    [47]
    ELMORSY EA, SABER S, HAMAD RS, et al. Modulating the HSP90 control over NFκB/NLRP3/caspase-1 axis is a new therapeutic target in the management of liver fibrosis: Insights into the role of TAS-116(pimitespib)[J]. Life Sci, 2024, 354: 122966. DOI: 10.1016/j.lfs.2024.122966.
    [48]
    RAMOS-TOVAR E, MURIEL P. NLRP3 inflammasome in hepatic diseases: A pharmacological target[J]. Biochem Pharmacol, 2023, 217: 115861. DOI: 10.1016/j.bcp.2023.115861.
    [49]
    SATHEESAN A, KUMAR J, LEELA KV, et al. Review on the role of nucleotide-binding oligomerization domain-like receptor protein 3(NLRP3) inflammasome pathway in diabetes: Mechanistic insights and therapeutic implications[J]. Inflammopharmacology, 2024, 32( 5): 2753- 2779. DOI: 10.1007/s10787-024-01556-2.
    [50]
    BARROW ER, VALIONYTE E, BAXTER CR, et al. Discovery of SQSTM1/p62-dependent P-bodies that regulate the NLRP3 inflammasome[J]. Cell Rep, 2024, 43( 3): 113935. DOI: 10.1016/j.celrep.2024.113935.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (253) PDF downloads(28) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2713]YesterdayPV[4302]TodayIP[1032]TodayPV[1591]Online[160]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return